Drugs / BGB-B2033
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06427941 | Jul 2024 → May 2028 expected | gastric cancer, hepatocellular carcinoma, non-small cell squamous lung carcinoma, yolk sac tumor | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB-B2033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06427941 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT06427941 ↗ |